Drug Trial Radar · NCT01476657
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
210
Actual
Start
Oct 2011
Primary completion
Dec 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- SecuraBioIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
Conditions
- Hematologic Malignancies
Interventions
IPI-145 (duvelisib)Drug
Oral Twice A Day (BID) Dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: At least 28 days (1 Cycle)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
New York, New York
Site not named
Columbus, Ohio
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.